PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1438719

[Bone marrow edema in MRT].

M Vahlensieck·M Reiser
View original source ↗Export metadata ↓

Abstract

Like other vascularized organs, bone can react with increasing interstitial fluid to disturbances in permeability caused by various noxae. Signs of bone marrow edema recognizable in magnetic resonance imaging are described for conditions such as trauma, stress, reflex sympathetic dystrophy, ischemia, and infection. A bone marrow edema may be an early or the only sign of a disease entity visible solely on MR images. We made a retrospective study of musculoskeletal MR examinations conducted over a period of 3 months to estimate the incidence of bone marrow edema.

Explore related subjects

Bone Marrow DiseasesEdemaGermanyHumansInflammationMagnetic Resonance ImagingRetrospective StudiesWounds and InjuriesEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Vahlensieck, M Reiser. 1992. [Bone marrow edema in MRT].. https://pubmed.ncbi.nlm.nih.gov/1438719/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

MRI findings in Shwachman diamond syndrome.

Shwachman Diamond Syndrome (SDS) is a rare congenital disorder characterized by pancreatic insufficiency, bone marrow dysfunction, and skeletal changes. Because of the heterogeneous clinical presentation and the limits of laboratory tests that assess pancreatic insufficiency, the diagnosis of SDS can be challenging. Pancreatic lipomatosis, a typical feature of this syndrome, is also difficult to assess by direct tissue sampling. In these circumstances, magnetic resonance imaging (MRI) provides a readily available, noninvasive tool to evaluate the pancreatic fat content. We report a case of a 12-month-old male in which abdominal MRI was used to confirm the clinical diagnosis of SDS.

Bone Marrow Diseases↗
PubMed2006

Nuclear medicine imaging and therapy of neuroendocrine tumours.

Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations.

Bone Marrow Diseases↗